Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

This study has been completed.

Study NCT00119249 Information provided by National Cancer Institute (NCI)

First Received: July 12, 2005 Last Updated: July 12, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Publications:

Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One. 2010 Dec 29;5(12):e15588.

Min C, Liebes L, Brooks P, et al.: Phase II trial of BAY 43-9006 (sorafenib-BAY) in metastatic melanoma (MM) including detection of BRAF mutations with mutant specific-PCR (MS-PCR) and altered proliferation pathways. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-B254, 2007.